Iressa Study in Patients With Salivary Gland Cancer
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help
to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The
safety of this drug will also be studied.